Work taking place in the clean rooms at Vor (Credit: Vor)

Vor Bio opts to keep man­u­fac­tur­ing op­er­a­tions in-house for de­vel­op­ing stem cell, CAR-T ther­a­pies

While it is not un­com­mon for a biotech to go down the route of hav­ing the prod­uct man­u­fac­tured by a con­tract or­ga­ni­za­tion, one small biotech is look­ing to keep its card close to its chest.

Vor Bio­phar­ma has start­ed man­u­fac­tur­ing op­er­a­tions at an in-house fa­cil­i­ty at its HQ in Cam­bridge, MA af­ter be­gin­ning con­struc­tion last sum­mer.

Ac­cord­ing to the biotech, the fa­cil­i­ty aims to de­vel­op Vor’s hematopoi­et­ic stem cells (eHSCs) and CAR-T ther­a­pies for pa­tients with blood can­cers. The site will ini­tial­ly man­u­fac­ture a clin­i­cal sup­ply of its can­di­date VCAR33al­lo to sup­port its IND, which is slat­ed to be sub­mit­ted in the first half of next year. It al­so plans to trans­fer the pro­duc­tion of VOR33 to the fa­cil­i­ty. Vor is get­ting to work quick­ly as en­gi­neer­ing runs for VCAR33al­lo has start­ed this week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.